A role for TLR signaling during B cell activation in antiretroviral-treated HIV individuals

AIDS Research and Human Retroviruses

Volumn 29, Issue 10, 2013, Pages 1353-1360

  Siewe, Basile ^a   Keshavarzian, Ali ^a,b   French, Audrey ^a,c   Demarais, Patricia ^c   Landay, Alan ^a,b  

^a RUSH UNIVERSITY   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD40 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOTEICHOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; B-LYMPHOCYTES; FEMALE; GENE EXPRESSION PROFILING; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84885131818     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0115     Document Type: Article

References (59)

1. Sodora DL and Silvestri G: Immune activation and AIDS pathogenesis. AIDS 2008;22(4):439-446. (Pubitemid 351317285)
2. Duprez DA, Neuhaus J, Kuller LH, et al.: Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012;7(9):e44454.
3. Neuhaus J, Jacobs DR Jr, Baker JV, et al.: Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;15;201(12):1788-1795.
4. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, and Detels R: Elevated levels of CD38 + CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993;6(8):904-912. (Pubitemid 23207458)
5. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, and Giorgi JV: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16(2):83-92.
6. Giorgi JV, Hultin LE, McKeating JA, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999;179(4):859-870. (Pubitemid 29159331)
7. Moir S and Fauci AS: B cells in HIV infection and disease. Nat Rev Immunol 2009;9(4):235-245.
8. Mandl JN, Barry AP, Vanderford TH, et al.: Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008;14(10):1077-1087.
9. Chang JJ and Altfeld M: TLR-mediated immune activation in HIV. Blood 2009;113(2):269-270.
10. Doyle S, Vaidya S, O'Connell R, et al.: IRF3 mediates a TLR3/ TLR4-specific antiviral gene program. Immunity 2002;17(3): 251-263. (Pubitemid 35279547)
11. Heggelund L, Damas JK, Yndestad A, et al.: Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: Possible pathogenic consequences. Clin Exp Immunol 2004;138(1):116-121. (Pubitemid 39279973)
12. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, and Lederman MM: Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 2008;3(4):e1915.
13. Takeda K, Kaisho T, and Akira S: Toll-like receptors. Annu Rev Immunol 2003;21:335-376. (Pubitemid 37174535)
14. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371. (Pubitemid 44924494)
15. Chang JJ, Lacas A, Lindsay RJ, et al.: Differential regulation of toll-like receptor pathways in acute and chronic HIV-1 infection. AIDS 2012;26(5):533-541.
16. Hernandez JC, Stevenson M, Latz E, and Urcuqui-Inchima S: HIV type 1 infection up-regulates TLR2 and TLR4 expression and function in vivo and in vitro. AIDS Res Hum Retroviruses 2012;28(10):1313-1328.
17. Hernandez JC, Arteaga J, Paul S, Kumar A, Latz E, and Urcuqui-Inchima S: Up-regulation of TLR2 and TLR4 in dendritic cells in response to HIV type 1 and coinfection with opportunistic pathogens. AIDS Res Hum Retroviruses 2011;27(10):1099-1109.
18. Heggelund L, Muller F, Lien E, et al.: Increased expression of toll-like receptor 2 on monocytes in HIV infection: Possible roles in inflammation and viral replication. Clin Infect Dis 2004;39(2):264-269. (Pubitemid 38971499)
19. Lester RT, Yao XD, Ball TB, et al.: Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS 2008;22(6):685-694. (Pubitemid 351450636)
20. Piconi S, Parisotto S, Rizzardini G, et al.: Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011;118(12):3263-3272.
21. Murray SM, Down CM, Boulware DR, et al.: Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84(22):12082-12086.
22. Baenziger S, Heikenwalder M, Johansen P, et al.: Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2009;113(2):377-388.
23. Haas A, Zimmermann K, and Oxenius A: Antigendependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol 2011;85(23):12102-12113.
24. Gray D, Gray M, and Barr T: Innate responses of B cells. Eur J Immunol 2007;37(12):3304-3310.
25. Duddy M and Bar-Or A: B-cells in multiple sclerosis. Int MS J 2006;13(3):84-90. (Pubitemid 44898369)
26. Audige A, Schlaepfer E, von Wyl V, et al.: B cells from HIVinfected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-alpha response to TLR9 triggering. AIDS Res Hum Retroviruses 2010;26(10):1063-1074.
27. Malaspina A, Moir S, DiPoto AC, et al.: CpG oligonucleotides enhance proliferative and effector responses of B cells in HIV-infected individuals. J Immunol 2008;181(2):1199-1206.
28. Jiang W, Lederman MM, Mohner RJ, et al.: Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol 2008; 82(16):7837-7845.
29. Agrawal S and Gupta S: TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 2011;31(1):89-98.
30. Dopper S, Wilflingseder D, Prodinger WM, et al.: Mechanism (s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures. Eur J Immunol 2003;33(8):2098-2107. (Pubitemid 37010026)
31. Rieckmann P, Poli G, Kehrl JH, and Fauci AS: Activated B lymphocytes from human immunodeficiency virusinfected individuals induce virus expression in infected T cells and a promonocytic cell line, U1. J Exp Med 1991; 173(1):1-5.
32. Poulin L, Paquette N, Moir S, Lapointe R, and Darveau A: Productive infection of normal CD40-activated human B lymphocytes by HIV-1. AIDS 1994;8(11):1539-1544. (Pubitemid 24335090)
33. De Milito A: B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2004;2(1):11-21. (Pubitemid 38854921)
34. Epeldegui M, Widney DP, and Martinez-Maza O: Pathogenesis of AIDS lymphoma: Role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 2006;18(5):444-448. (Pubitemid 44199839)
35. Breen EC, Hussain SK, Magpantay L, et al.: B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011;20(7):1303-1314.
36. Martinson JA, Roman-Gonzalez A, Tenorio AR, et al.: Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol 2007;250(1-2):75-84.
37. Yonkers NL, Rodriguez B, Asaad R, Lederman MM, and Anthony DD: Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells. PLoS One 2011;6(9):e23884.
38. Roux PP and Blenis J: ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68(2):320-344. (Pubitemid 38756868)
39. Redford TW, Yi AK, Ward CT, and Krieg AM: Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol 1998; 161(8):3930-3935. (Pubitemid 28468968)
40. Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, and Tomai MA: Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol 2000;165(10):5552-5557.
41. Ray A, Cot M, Puzo G, Gilleron M, and Nigou J: Bacterial cell wall macroamphiphiles: Pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. Biochimie 2013;95(1):33-42.
42. Seo HS, Michalek SM, and Nahm MH: Lipoteichoic acid is important in innate immune responses to gram-positive bacteria. Infect Immun 2008;76(1):206-213.
43. Ginsburg I: Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2002;2(3):171-179. (Pubitemid 34462452)
44. Hunt PW: HIV and inflammation: Mechanisms and consequences. Curr HIV/AIDS Rep 2012;9(2):139-147.
45. Bekeredjian-Ding I and Jego G: Toll-like receptors-sentries in the B-cell response. Immunology 2009;128(3):311-323.
46. Dasari P, Nicholson IC, Hodge G, Dandie GW, and Zola H: Expression of toll-like receptors on B lymphocytes. Cell Immunol 2005;236(1-2):140-145. (Pubitemid 41771098)
47. Duddy M, Niino M, Adatia F, et al.: Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178(10): 6092-6099. (Pubitemid 46717389)
48. Kehrl JH, Rieckmann P, Kozlow E, and Fauci AS: Lymphokine production by B cells from normal and HIV-infected individuals. Ann NY Acad Sci 1992;651:220-227.
49. Vanden Bush TJ and Bishop GA: TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol 2008;38(2):400-409.
50. Jagannathan M, McDonnell M, Liang Y, et al.: Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia 2010;53(7):1461-1471.
51. Nikolajczyk BS: B cells as under-appreciated mediators of non-auto-immune inflammatory disease. Cytokine 2010; 50(3):234-242.
52. Apetrei C, Pandrea I, and Mellors JW: Nonhuman primate models for HIV cure research. PLoS Pathog 2012;8(8): e1002892.
53. Rodriguez-Garcia M, Porichis F, de Jong OG, et al.: Expression of PD-L1 and PD-L2 on human macrophages is upregulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol 2011;89(4):507-515.
54. Poovassery JS, Vanden Bush TJ, and Bishop GA: Antigen receptor signals rescue B cells from TLR tolerance. J Immunol 2009;183(5):2974-2983.
55. Jiang W, Lederman MM, Hunt P, et al.: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009;199(8): 1177-1185.
56. Heil F, Hemmi H, Hochrein H, et al.: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303(5663):1526- 1529. (Pubitemid 38314424)
57. Mureith MW, Chang JJ, Lifson JD, Ndung'u T, and Altfeld M: Exposure to HIV-1-encoded Toll-like receptor 8 ligands enhances monocyte response to microbial encoded Toll-like receptor 2/4 ligands. AIDS 2010;24(12):1841-1848.
58. Antosz H, Sajewicz J, Marzec-Kotarska B, Dmoszynska A, Baszak J, and Jargiello-Baszak M: TLR2 may influence the behavior of the malignant clone in B-CLL. Blood Cells Mol Dis 2012;49(1):32-40.
59. Smith TJ, Yamamoto K, Kurata M, et al.: Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp Mol Pathol 2010;89(3):284-290.